To investigate the rate of progression free survival at 6 months in a comparable population of patients with inoperable cholangiocarcinoma treated with either GOC and panitumumab or GOC and bevacizumab
Data and Resources
- Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutationsjson
To investigate the rate of progression free survival at 6 months in a...
|Release Date|| |
License Not Specified
|Public Access Level|| |